Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1467335 Brain MAO-B Occupancy Study
NCT03927209Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PXS-4728A in Nonalcoholic steatohepatitis (NASH) and diabetic retinopathy (DR) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage Reduction in Whole Brain Monoamine Oxidase (MAO)-B Availability at Day 42. Started Jun 2019; status: completed.
02
Drugs
PXS-4728A
03
Conditions
Nonalcoholic steatohepatitis (NASH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03927209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927209.